Want to see HK:2161 full AI Analyst Report?
2161 Stock Chart & Stats
HK$2.77
-HK$0.02(-1.12%)
At close: 4:00 PM EST
HK$2.77
-HK$0.02(-1.12%)
Day’s Range― - ―
52-Week RangeHK$1.84 - HK$3.43
Previous CloseN/A
Volume460.00K
Average Volume (3M)599.79K
Market Cap
HK$1.65B
Enterprise ValueHK$2.10B
Total Cash (Recent Filing)HK$194.20M
Total Debt (Recent Filing)HK$383.18M
Price to Earnings (P/E)8.0
Beta0.17
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield9.98%
Share Statistics
EPS (TTM)0.26
Shares Outstanding822,000,000
10 Day Avg. Volume515,131
30 Day Avg. Volume599,792
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.36
Price to Sales (P/S)1.87
P/FCF Ratio7.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.15Price Target Upside13.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.3
Revenue Forecast (FY)HK$935.78M
Bulls Say, Bears Say
Bulls Say
High Profitability And Revenue GrowthConsistent revenue growth coupled with very high gross and operating margins indicates durable business economics and pricing power. Strong EBIT/EBITDA margins support reinvestment, high retained cash generation and the ability to sustain R&D, product development and dividend programs over time.
Strong Balance Sheet With Low LeverageVery low leverage and a high equity ratio provide financial flexibility to withstand industry cycles and fund strategic investments without heavy refinancing. A ROE near 18% indicates efficient capital use, supporting sustainable shareholder returns and lower solvency risk.
Solid Cash Conversion Relative To EarningsCash conversion metrics close to parity with net income show the business generates real cash to support operations, capex and distributions. This durability in cash generation underpins long-term funding of growth and cushions the balance sheet against temporary earnings volatility.
Bears Say
Declining Free Cash Flow GrowthA near-20% drop in free cash flow growth is a structural warning sign if it continues: it can reduce capacity for dividends, M&A or deleveraging. Persistent declines could reflect higher capex, inventory build or weaker collections that impair long-term financial flexibility.
Operating Cash Below Reported EarningsOCF materially below net income suggests part of reported profits may be driven by non-cash items or timing effects. Over the medium term, this gap can pressure liquidity and raise questions on earnings quality if working capital or accruals remain elevated.
Modest Scale And Limited Market LiquidityA relatively small workforce and limited trading volume signal constrained operational scale and lower institutional liquidity. This can restrict capacity for rapid scaling of R&D or commercial rollout and makes large capital moves or secondary financing more challenging.
JBM (Healthcare) Ltd. News
2161 FAQ
What was JBM (Healthcare) Ltd.’s price range in the past 12 months?
JBM (Healthcare) Ltd. lowest stock price was HK$1.84 and its highest was HK$3.43 in the past 12 months.
What is JBM (Healthcare) Ltd.’s market cap?
JBM (Healthcare) Ltd.’s market cap is HK$1.65B.
When is JBM (Healthcare) Ltd.’s upcoming earnings report date?
JBM (Healthcare) Ltd.’s upcoming earnings report date is Nov 20, 2026 which is in 141 days.
How were JBM (Healthcare) Ltd.’s earnings last quarter?
JBM (Healthcare) Ltd. released its earnings results on Jun 22, 2026. The company reported HK$0.105 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.105.
Is JBM (Healthcare) Ltd. overvalued?
According to Wall Street analysts JBM (Healthcare) Ltd.’s price is currently Undervalued.
Does JBM (Healthcare) Ltd. pay dividends?
JBM (Healthcare) Ltd. pays a Quarterly dividend of HK$0.073 which represents an annual dividend yield of 9.98%. See more information on JBM (Healthcare) Ltd. dividends here
What is JBM (Healthcare) Ltd.’s EPS estimate?
JBM (Healthcare) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JBM (Healthcare) Ltd. have?
JBM (Healthcare) Ltd. has 822,000,000 shares outstanding.
What happened to JBM (Healthcare) Ltd.’s price movement after its last earnings report?
JBM (Healthcare) Ltd. reported an EPS of HK$0.105 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.437%.
Which hedge fund is a major shareholder of JBM (Healthcare) Ltd.?
Currently, no hedge funds are holding shares in HK:2161
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JBM (Healthcare) Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$3.15 (13.72% Upside)
HK$3.15 (13.72% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.77%
12-Months-Change
Fundamentals
Return on Equity
20.10%
Trailing 12-Months
Asset Growth
14.08%
Trailing 12-Months
Company Description
JBM (Healthcare) Ltd.
JBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
2161 Stock 12 Month Forecast
Average Price Target
HK$3.15
▲(13.72% Upside)
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―
Options Prices
Currently, No data available
---